In short
Clinical trials are investigating Aliskiren in people with C3 glomerulopathy, a kidney disease linked to the complement system. The main goal is to see whether it can help lower disease activity, protect kidney function, and how it compares with enalapril. These studies also look at safety and measures of complement activation.
Key points
- Clinical trials of Aliskiren are being done in people with C3 glomerulopathy, a complement-mediated kidney disease. The main study in the data is a Phase 2 interventional trial with 30 participants. Researchers are comparing Aliskiren with enalapril and looking at whether it can reduce complement activity. Key outcomes include serum C3 in the cross-over study and serum C3 plus complement deposition in kidney biopsies during the extension study. The trial also aims to assess safety and possible effects on kidney function. The study is completed.
Trial overview
The clinical trial in the source data studied Aliskiren in people with C3 glomerulopathy, which is a kidney disease linked to the complement system.
This was a Phase 2 interventional study, and it was completed with 30 enrolled participants.
The study aimed to assess whether Aliskiren could help reduce complement activation in the kidneys and support better kidney outcomes.
Study design and treatment comparison
The trial compared Aliskiren with enalapril, which was the currently used treatment in this study setting.
The treatment arms listed in the source were oral Rasilez 300 mg film-coated tablets and oral Enalapril Viatris 5 mg comprimidos EFG.
The brief summary says the project used a cross-over study and an extension study.
In a cross-over study, the same people receive different treatments in a planned order so results can be compared more fairly within the same patient group.
Who participated
The study was designed for patients with C3 glomerulopathy.
The trial data do not give more detailed inclusion or exclusion rules, so the main known target group is people with this kidney disease.
This makes the study relevant to a rare group of patients whose disease is linked to abnormal complement activity in the kidney.
What was measured
The main outcome in the cross-over part was serum C3.
Serum C3 is a blood marker related to the complement system, and changes in this marker can show whether disease activity is going up or down.
In the extension study, the trial measured serum C3 again and also looked at complement deposition in renal biopsies.
A renal biopsy is a small sample of kidney tissue, and complement deposition means build-up of complement proteins in that tissue.
The brief summary also says the study assessed safety and looked for signs of reduced systemic and local complement activation.
Why this trial matters
This trial is important because it focuses on a disease where the complement system may damage the kidneys.
By comparing Aliskiren with enalapril, researchers were trying to see whether Aliskiren could offer a different way to manage this condition.
The study also used tissue and blood markers, which can help show whether a treatment changes the disease process, not just symptoms.